kallikrein related peptidase 15Genealiases: ACO · HSRNASPH
Q-omics provides the consensus-scored KLK15 profile across patient tissues and cancer cell-line models. KLK15 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, KLK15 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, KLK15 RNA expression shows 9,986 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, COAD, and TGCT as cancer lineages where KLK15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLK15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLK15 survival associations across molecular data types. KLK15 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLK15 RNA expression–survival associations across cancer types. High KLK15 expression shows unfavorable associations in KIRC, BLCA, THYM and BRCA, but favorable associations in ACC and UVM. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for KLK15 RNA expression.
This table summarizes KLK15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for KLK15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLK15 shows lower tumor expression in COAD, THCA, KIRC and KIRP and higher tumor expression in KICH and LUSC. The COAD box plot shows higher KLK15 RNA expression in normal versus tumor tissue (log2 FC = −1.330, t-test p < 0.001).
This table shows molecular features associated with KLK15 in patient tissues and cancer cell lines. In patient samples, KLK15 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, KLK15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and OESOPHAGUS.
